Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Authors
Keywords
-
Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 329, Issue 1, Pages 63
Publisher
American Medical Association (AMA)
Online
2022-12-02
DOI
10.1001/jama.2022.22246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and immunogenicity of SARS-CoV-2 mRNA-1273 and BNT162b2 vaccines in people living with HIV
- (2022) Manuel González de Aledo et al. AIDS
- Impaired antibody response to COVID-19 vaccination in advanced HIV infection
- (2022) Nolan Hassold et al. AIDS
- Strategies to improve HIV care outcomes for people with HIV who are out of care
- (2022) Darrel H. Higa et al. AIDS
- Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study
- (2022) Ghady Haidar et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine (DTG/3TC) Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With HIV-1: Results Through Week 144 From the Phase 3, Non-inferiority TANGO Randomized Trial
- (2022) Olayemi Osiyemi et al. CLINICAL INFECTIOUS DISEASES
- SARS-CoV-2 testing and positivity among persons with and without HIV in 6 United States cohorts
- (2022) Lesley S. Park et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- How health systems can adapt to a population ageing with HIV and comorbid disease
- (2022) Jepchirchir Kiplagat et al. Lancet HIV
- Delayed presentation of HIV among older individuals: a growing problem
- (2022) Amy C Justice et al. Lancet HIV
- Association Between Social Vulnerability and Rates of HIV Diagnoses Among Black Adults, by Selected Characteristics and Region of Residence — United States, 2018
- (2022) André F. Dailey et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Impact of the COVID-19 Pandemic on the UNAIDS Six 95% HIV Control Targets
- (2022) Tiande Jiang et al. Frontiers in Medicine
- Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily
- (2022) Sanjana Mitra et al. AIDS AND BEHAVIOR
- Geriatric conditions and healthcare utilisation in older adults living with HIV
- (2022) Meredith Greene et al. AGE AND AGEING
- High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I
- (2022) Paul E. Sax et al. AIDS
- Abnormal cognitive aging in people with HIV: Evidence from Data Integration between two countries’ cohort studies
- (2022) Htein Linn Aung et al. AIDS
- High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?
- (2022) Xinling Xu et al. AIDS
- Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size
- (2022) Thomas A Rasmussen et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial
- (2022) Josep M Llibre et al. CLINICAL INFECTIOUS DISEASES
- Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV
- (2022) Jane A O’Halloran et al. CLINICAL INFECTIOUS DISEASES
- Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020.
- (2022) Adrienne E. Shapiro et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
- (2022) Sinead Delany-Moretlwe et al. LANCET
- Covid-19 vaccine immunogenicity in people living with HIV-1
- (2022) Lauriane Nault et al. VACCINE
- Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection
- (2022) Katja G. Schmidt et al. Viruses-Basel
- Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA
- (2022) Maria Mazzitelli et al. Viruses-Basel
- Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
- (2022) Ainsley Ryan Yan Bin Lee et al. BMJ-British Medical Journal
- Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study
- (2022) Jennifer S Lee et al. Lancet HIV
- Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
- (2022) Shabir A Madhi et al. Lancet HIV
- Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
- (2022) Nicholas I Paton et al. Lancet HIV
- Persistent disparities in COVID-19-associated impacts on HIV prevention and care among a global sample of sexual and gender minority individuals
- (2022) Glenn-Milo Santos et al. Global Public Health
- The Impact of Frailty on All-Cause Mortality in Patients with HIV Infection: A Systematic Review and Meta-Analysis
- (2022) Shanshan Liu et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France
- (2022) Valentine Marie Ferré et al. ANNALS OF INTERNAL MEDICINE
- First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic
- (2022) Katerina A Christopoulos et al. CLINICAL INFECTIOUS DISEASES
- Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial
- (2022) Antoine Chéret et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
- (2022) John P. Thornhill et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV Testing Before and During the COVID-19 Pandemic — United States, 2019–2020
- (2022) Elizabeth A. DiNenno et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
- (2022) Sally B. Coburn et al. JAMA Network Open
- Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV
- (2022) Nadine Jaschinski et al. AIDS
- Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States
- (2022) Kunjal Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses
- (2021) Patrick S Sullivan et al. LANCET
- Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
- (2021) Nathalie De Castro et al. LANCET INFECTIOUS DISEASES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Awareness of and willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs and men who have sex with men in India: Results from a multi-city cross-sectional survey
- (2021) Ashwin Belludi et al. PLoS One
- Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression
- (2021) Preeti Pathela et al. AIDS
- Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
- (2021) Bernard Surial et al. ANNALS OF INTERNAL MEDICINE
- Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV
- (2021) Sarah M. Michienzi et al. Current Infectious Disease Reports
- Overview of SARS-CoV-2 infection in adults living with HIV
- (2021) Juan Ambrosioni et al. Lancet HIV
- Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus
- (2021) Nathanial S Nolan et al. Open Forum Infectious Diseases
- Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
- (2021) Pierre-Emmanuel Plum et al. BMC INFECTIOUS DISEASES
- Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
- (2021) Marina Treskova-Schwarzbach et al. BMC Medicine
- Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus
- (2021) Amelia J Davis et al. CLINICAL INFECTIOUS DISEASES
- The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
- (2021) Bezawit A Woldemeskel et al. CLINICAL INFECTIOUS DISEASES
- Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus
- (2021) Ronald J Ellis et al. CLINICAL INFECTIOUS DISEASES
- Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
- (2021) Debbie Hagins et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients
- (2021) Charlotte Charpentier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
- (2021) Ana González-Cordón et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
- (2021) Raphael J. Landovitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV
- (2021) Jeffrey V. Lazarus et al. Nature Communications
- Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study
- (2021) Robin Schaefer et al. Lancet HIV
- Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Onyema Ogbuagu et al. Lancet HIV
- A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
- (2021) Katelyn F McNamara et al. Open Forum Infectious Diseases
- The shifting age distribution of people with HIV using antiretroviral therapy in the United States
- (2021) Keri N. Althoff et al. AIDS
- Safer in care: A pandemic-tested model of integrated HIV/OUD care
- (2021) Ellen F. Eaton et al. DRUG AND ALCOHOL DEPENDENCE
- Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
- (2021) Daniel K Nomah et al. Lancet HIV
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
- (2021) Kim A. Hoffman et al. Addiction Science & Clinical Practice
- Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions
- (2021) Noor Taweh et al. INTERNATIONAL JOURNAL OF DRUG POLICY
- Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder
- (2021) Lori Beck et al. JOURNAL OF SUBSTANCE ABUSE TREATMENT
- Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
- (2021) Susan H Eshleman et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study
- (2020) Jean van Wyk et al. CLINICAL INFECTIOUS DISEASES
- Antiretroviral therapy in older people with HIV
- (2020) Aaron Richterman et al. Current Opinion in HIV and AIDS
- The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
- (2020) Jennifer Gorwood et al. CLINICAL INFECTIOUS DISEASES
- Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy
- (2020) Jenna L. Yager et al. Expert Opinion on Drug Metabolism & Toxicology
- Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics
- (2020) Sandra A. Springer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Rapid antiretroviral therapy among individuals with acute and early HIV
- (2020) Thomas C S Martin et al. CLINICAL INFECTIOUS DISEASES
- Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen
- (2020) Jean van Wyk et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
- (2020) Jennifer A Smith et al. JOURNAL OF INFECTIOUS DISEASES
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models
- (2020) Britta L Jewell et al. Lancet HIV
- Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam
- (2020) Jonathan Feelemyer et al. AIDS
- Hazardous alcohol use, antiretroviral therapy receipt and viral suppression in people living with HIV who inject drugs in the U.S., India, Russia and Vietnam
- (2020) Jennifer A. Wagman et al. AIDS
- Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19
- (2020) Dima Dandachi et al. CLINICAL INFECTIOUS DISEASES
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens
- (2020) Michael A Leonard et al. CLINICAL INFECTIOUS DISEASES
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
- (2020) Willem D F Venter et al. Lancet HIV
- Could disparities in PrEP uptake limit the public health benefit?
- (2020) Phillip Keen et al. Lancet Public Health
- Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV
- (2020) Lauren Greenberg et al. CLINICAL INFECTIOUS DISEASES
- COVID-19 infection among people with HIV in New York City: A population-level analysis of linked surveillance data
- (2020) Sarah L Braunstein et al. CLINICAL INFECTIOUS DISEASES
- Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals
- (2020) Kathy Petoumenos et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis
- (2019) Kimia Kamelian et al. Open Forum Infectious Diseases
- Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
- (2019) Laura Fanucchi et al. Current HIV/AIDS Reports
- Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
- (2019) Michael Aboud et al. LANCET INFECTIOUS DISEASES
- Impact of abstinence and of reducing illicit drug use without abstinence on HIV viral load
- (2019) Robin M Nance et al. CLINICAL INFECTIOUS DISEASES
- ART reduces T cell activation and immune exhaustion markers in HIV controllers
- (2019) Jonathan Z Li et al. CLINICAL INFECTIOUS DISEASES
- Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting
- (2019) Nongodo Firmin Kaboré et al. BMC Nephrology
- Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART
- (2019) Juan Berenguer et al. PLoS One
- Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study
- (2019) Perrine Courlet et al. AIDS
- A Call to Action: The Role of Antiretroviral Stewardship in Inpatient Practice, a Joint Policy Paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine
- (2019) David E Koren et al. CLINICAL INFECTIOUS DISEASES
- Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa
- (2019) Sarah B. Puryear et al. AIDS
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study
- (2019) Gregory D Huhn et al. CLINICAL INFECTIOUS DISEASES
- Deprescribing of non-antiretroviral therapy in HIV-infected patients
- (2019) José-Ramón Blanco et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Outcomes Following the Use of Archived Proviral HIV-1 DNA Genotype to Guide Antiretroviral Therapy Adjustment
- (2019) Kristen E Ellis et al. Open Forum Infectious Diseases
- Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases
- (2019) Nikhil Seval et al. Open Forum Infectious Diseases
- Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda
- (2019) Sandra A Springer et al. JOURNAL OF INFECTIOUS DISEASES
- Extended-release naltrexone improves viral suppression levels in prisoners with HIV and alcohol use disorders who are transitioning to the community
- (2018) Sandra A. Springer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
- (2018) Sandra A. Springer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia
- (2018) Kedar Joshi et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- HIV Infection, Tenofovir, and Urine α 1 -Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study
- (2016) Vasantha Jotwani et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity
- (2015) Meghan E. Sise et al. AIDS
- Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective
- (2015) Sandra A. Springer et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
- (2014) Beatriz Grinsztejn et al. LANCET INFECTIOUS DISEASES
- Contingency Management Facilitates the Use of Post-Exposure Prophylaxis among Stimulant-using Men Who Have Sex with Men
- (2014) R. J. Landovitz et al. Open Forum Infectious Diseases
- Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria
- (2012) A Samarawickrama et al. HIV MEDICINE
- Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
- (2012) Sandra A. Springer et al. PLoS One
- Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial
- (2011) Timothy W Menza et al. BMC PUBLIC HEALTH
- Unknown
- (2009) JOURNAL OF INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now